These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 5911902)

  • 21. [Studies on the treatment of malignant tumor with fibroblast-inhibiting agents].
    Hiraki K; Kimura I; Kageyama H; Kawanishi K; Moritani Y
    Gan No Rinsho; 1966 Aug; 12(8):499-511. PubMed ID: 6011017
    [No Abstract]   [Full Text] [Related]  

  • 22. Nephrotoxic action of snake venoms.
    Raab W; Kaiser E
    Mem Inst Butantan; 1966; 33(3):1017-20. PubMed ID: 6002955
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD; Scharf O; Schoenfeldt M
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract]   [Full Text] [Related]  

  • 24. Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?
    Chamberlain MC
    J Clin Oncol; 2009 Apr; 27(11):1921; author reply 1922. PubMed ID: 19255301
    [No Abstract]   [Full Text] [Related]  

  • 25. Distribution of low molecular weight platelet aggregation inhibitors from snake venoms.
    Oyama E; Takahashi H
    Toxicon; 2007 Mar; 49(3):293-8. PubMed ID: 17141819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The pharmacological properties of preparations from the aziridinyl triazine group].
    Stukov AN; Filov VA; Kon'kov SA; Ivin BA
    Eksp Klin Farmakol; 1996; 59(1):58-60. PubMed ID: 8704637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gluconeogenesis during therapy of experimental tumors with hydrazine sulfate].
    Filov VA; Burova TM
    Biull Eksp Biol Med; 1984 Jan; 97(1):73-4. PubMed ID: 6692028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzymes of snake venoms as tools in biochemical research.
    Zeller EA
    Mem Inst Butantan; 1966; 33(2):349-57. PubMed ID: 6012213
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental methodology for the selection of potential anticancer agents].
    Pérez Mínguez F; Llombart Bosch A
    Rev Esp Oncol; 1982; 29(4):593-602. PubMed ID: 6927364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venom of Indian monocellate cobra and Russell's viper show anticancer activity in experimental models.
    Debnath A; Chatterjee U; Das M; Vedasiromoni JR; Gomes A
    J Ethnopharmacol; 2007 May; 111(3):681-4. PubMed ID: 17258413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of thioproline on experimental arrhythmia].
    Zhao HP; Feng GH
    Zhongguo Yao Li Xue Bao; 1984 Mar; 5(1):30-2. PubMed ID: 6232816
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological and immunological properties of nerve growth factor from snake venoms.
    Lipps BV
    J Nat Toxins; 1998 Jun; 7(2):121-30. PubMed ID: 9678186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the prophylactic and therapeutic effect of Bothropase in vaccinia in animals and man].
    Bassetti D; Giacchino R
    G Mal Infett Parassit; 1969 Dec; 21(12):950-3. PubMed ID: 5397347
    [No Abstract]   [Full Text] [Related]  

  • 34. Coagulant and anticoagulant actions of Australian snake venoms.
    Marshall LR; Herrmann RP
    Thromb Haemost; 1983 Oct; 50(3):707-11. PubMed ID: 6648891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crotalid snake venom subproteomes unraveled by the antiophidic protein DM43.
    Rocha SL; Neves-Ferreira AG; Trugilho MR; Chapeaurouge A; León IR; Valente RH; Domont GB; Perales J
    J Proteome Res; 2009 May; 8(5):2351-60. PubMed ID: 19267469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunopharmacologic activity of toxins of animal origin (review of the literature)].
    Seĭfulla RD; Orlov BN; Romanova EB
    Farmakol Toksikol; 1981; 44(2):238-44. PubMed ID: 6115765
    [No Abstract]   [Full Text] [Related]  

  • 37. Integrin inhibitors reaching the clinic.
    Stupp R; Ruegg C
    J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
    [No Abstract]   [Full Text] [Related]  

  • 38. [Some methods of raising the selectivity of action of antineoplastic drugs].
    Sof'ina ZP; Lagova ND; Lesnaia NA; Babushkina NA
    Vestn Akad Med Nauk SSSR; 1984; (5):70-7. PubMed ID: 6741252
    [No Abstract]   [Full Text] [Related]  

  • 39. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
    Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds.
    Son DJ; Lee JW; Lee YH; Song HS; Lee CK; Hong JT
    Pharmacol Ther; 2007 Aug; 115(2):246-70. PubMed ID: 17555825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.